Frontiers in Immunology | Cancer Immunity and Immunotherapy

Original Research

Accepted on 12 May 2025

Integrated Multi-Omics Analysis and Experimental Investigation of Mitochondrial Dynamics-Related Genes: Molecular Subtypes, Immune Landscape, and Prognostic Implications in Lung Adenocarcinoma

in Cancer Immunity and Immunotherapy

Sixuan Wu
Junfan Pan
Lijun Zeng
Qihong Pan
Yao Yu
Jincan Lin
Jing Zhang
Yiling Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1585505

Correction

Accepted on 12 May 2025

Corrigendum: Characterization of TLR9 responsiveness in cell subsets derived from in vitro pDC differentiation of hematopoietic stem and progenitor cells

in Cancer Immunity and Immunotherapy

Sabina Sanchez Hernandez
Tobias Wang Bjerg
Ian Helstrup Nielsen
Anders Laustsen
Hai Q Tang
Lars Henning Pedersen
Eynav Klechevsky
Martin R. Jakobsen
Rasmus O Bak

Frontiers in Immunology

doi 10.3389/fimmu.2025.1625107

Mini Review

Accepted on 12 May 2025

T Lymphocyte Heterogeneity in NSCLC: Implications for Biomarker Development and Therapeutic Innovation

in Cancer Immunity and Immunotherapy

Yu Liu
Denghui Qin
Jiejun Fu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1604310

158 views

Original Research

Accepted on 12 May 2025

Radiation therapy for intestinal barrier damage and repair process -Differences in salivary metabolites and non-invasive monitoring of intestinal barrier function

in Cancer Immunity and Immunotherapy

Jingjing Zhang
Kun Wang
Yanyu Qiao
Mengjie Zhang
Yunqing Chen
Yulong Tian
Xuelong Jiao
Xiaojie Tan
Haitao Jiang
Feng Hou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1590219

Original Research

Accepted on 12 May 2025

Splenic Volume as a Predictor of Survival in Cancer Patients Treated with Immune Checkpoint Inhibitors

in Cancer Immunity and Immunotherapy

Yunhua Zhang
Xin Fu
Lilong Zhang
Qing Zhou
Weixing Wang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1598484

Original Research

Accepted on 12 May 2025

PSMD12 Promotes Hepatocellular Carcinoma Progression by Stabilizing CDK1

in Cancer Immunity and Immunotherapy

Xingyu Peng
Zitao Liu
Luo Chen
Rui Sun
Yuting Zhang
Bowen Li
Yeqing Zou
Jinfeng Zhu
Rongfa Yuan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1581398

Systematic Review

Accepted on 12 May 2025

The Efficacy and Safety of Regorafenib/Fruquintinib Combined with PD-1/PD-L1 for Metastatic Colorectal Cancer: A Meta-Analysis Based on Single-Arm Studies

in Cancer Immunity and Immunotherapy

Fan Yang
Ying Mao
Hanyu Huang
Wen Luo
Li Liu
Wenzhi Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1579293

110 views

Original Research

Accepted on 12 May 2025

Exploring and validating a guanylate-binding protein signature to predict the prognostic features of patients with lung adenocarcinoma

in Cancer Immunity and Immunotherapy

Yue Li
Wei Tian
Chen Chen
Hailin Liu
Zhenfa Zhang
Changli Wang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1588663

Original Research

Accepted on 12 May 2025

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging

in Cancer Immunity and Immunotherapy

Wei-hao Zhang
Zhao Xiao-Hui
Wei Gao
Tongguo Si
Qiang Zou
Xueling Yang
Wenge XING
Haipeng Yu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1596864

Original Research

Accepted on 12 May 2025

Baseline profile peripheral Tfh cells predict immune-related adverse events in immune checkpoint inhibitor therapy of gastrointestinal cancer

in Cancer Immunity and Immunotherapy

Yifan Wang
Zhening Zhang
Jing He
Zhi Peng
Tong Xie
YUDONG LIU
Cheng Zhang
Hao Li
Ruiling Feng
Bo Huang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1559275

Original Research

Accepted on 12 May 2025

Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy

in Cancer Immunity and Immunotherapy

Michael Lofgren
Lindsay Webb
Troy Patterson
Amy Watt
Jason Lajoie
Adam Zieba
Michelle Fleury
Erica Liu
Jian Ding
Robert Tighe

Frontiers in Immunology

doi 10.3389/fimmu.2025.1609658

Original Research

Accepted on 12 May 2025

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study

in Cancer Immunity and Immunotherapy

Baoyue Pan
He Huang
Ting Wan
Qidan Huang
Shanyang He
Shijie Xu
Siyu Chen
Jiaxin Yin
Jundong Li
Min Zheng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1582299

Mini Review

Accepted on 12 May 2025

T Cell Exhaustion in Pediatric B-ALL: Current Knowledge and Future Perspectives

in Cancer Immunity and Immunotherapy

Tanmaya Atre
Gregor S.D Reid

Frontiers in Immunology

doi 10.3389/fimmu.2025.1531145

Systematic Review

Accepted on 12 May 2025

EFFECT OF IMMUNE CHECKPOINT INHIBITOR THERAPY ON BIVENTRICULAR MECHANICS IN CANCER PATIENTS OVER A SHORT-TERM FOLLOW-UP: A SYSTEMATIC REVIEW

in Cancer Immunity and Immunotherapy

Andrea Sonaglioni
Antonino Bruno
Gian Luigi Nicolosi
Emanuela Fossile
Riccardo Ricotta
Maria Gemelli
Michele Lombardo
Paola Muti
Barbara Bassani

Frontiers in Immunology

doi 10.3389/fimmu.2025.1576175

Brief Research Report

Accepted on 12 May 2025

Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation

in Cancer Immunity and Immunotherapy

Maoqiong Hu
Renyi Yin
Kaifeng Deng
Ning Xu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1602189

Original Research

Published on 12 May 2025

Single-cell atlas of endothelial cells in atherosclerosis: identifying C1 CXCL12+ ECs as key proliferative drivers for immunological precision therapeutics in atherosclerosis

in Cancer Immunity and Immunotherapy

Zhenzhen Zhao
Yujiang Dong
Zhijie Zhao
Zhikai Xiahou
Cong Sun

Frontiers in Immunology

doi 10.3389/fimmu.2025.1569988

274 views